Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice

Journal of Neuroimmunology

Volumn 212, Issue 1-2, 2009, Pages 93-101

  Bizario, João Carlos da Silva ^a   Cerri, Daniel Giuliano ^a   Rodrigues, Lilian Cataldi ^a,b   Oliveira, Gislane L V ^b   Nomizo, Auro ^b   de Araujo, Daniela Dover ^a,b   Fukuhara, Paula Sakemi ^a   Ribeiro, Juliana Caldas ^a   de Castro, Fabíola Attié ^b   Costa, Maria Cristina Ramos ^a,b  

^a UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Duchenne muscular dystrophy; Fibrosis; Imatinib mesylate; Immunomodulation; mdx mice; Transforming growth factor 1

Indexed keywords

CREATINE KINASE; CYTOKINE; IMATINIB; INTERLEUKIN 10; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIAPHRAGM; DUCHENNE MUSCULAR DYSTROPHY; GASTROCNEMIUS MUSCLE; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; MOUSE; MUSCLE CELL; MUSCLE EXERCISE; MUSCLE STRENGTH; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 67649871093     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.05.006     Document Type: Article

References (50)

1. Albesiano E., Messmer B.T., Damle R.N., Allen S.L., Rai K.R., and Chiorazzi N. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 102 (2003) 3333-3339
2. Andreetta F., Bernasconi P., Baggi F., Ferro P., Oliva L., Arnoldi E., Cornelio F., Mantegazza R., and Confalonieri P. Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J. Neuroimmunol. 175 (2006) 77-86
3. Atallah E., Kantarjian H., and Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat. Med. 13 (2007) 14
4. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., Apperley J., Cervantes F., Cortes J., Deininger M., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R., Niederwieser D., Silver R., Hehlmann R., and European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
5. Blake D.J., Weir A., Newey S.E., and Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82 (2002) 291-329
6. Bogdanovich S., Perkins K.J., Krag T.O., Whittemore L.A., and Khurana T.S. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J. 19 (2005) 543-549
7. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331 (1994) 1286-1292
8. Bulfield G., Siller W.G., Wight P.A.L., and Moore K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 1189-1192
9. Cerri D.G., Rodrigues L.C., Stowell S.R., Araujo D.D., Coelho M.C., Oliveira S.R., Bizario J.C.S., Cummings R.D., Dias-Baruffi M., and Costa M.C.R. Degeneration of dystrophic or injured skeletal muscles induces high expression of galectin-1. Glycobiology 18 11 (2008) 842-850
10. Coirault C., Pignol B., Cooper R.N., Butler-Browne G., Chabrier P.E., and Lecarpentier Y. Severe muscle dysfunction precedes collagen tissue proliferation in mdx mouse diaphragm. J. Appl. Physiol. 94 (2003) 1744-1750
11. Collins C.A., and Morgan J.E. Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int. J. Exp. Pathol. 84 (2003) 165-172
12. Cwynarsky K., Laylor R., Macchiarulo E., Goldman J., Lombardi G., Melo J.V., and Dazzi F. Imatinib inhibits activation and proliferation of normal T lymphocytes in vitro. Leukemia 18 (2004) 1332-1339
13. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., and Leof E.B. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 114 (2004) 1308-1316
14. Davies K.E., and Nowak K. Molecular mechanisms of muscular dystrophies: old and new players. Nat. Rev. Mol. Cell Biol. 7 (2006) 762-773
15. Deconinck N., and Dan B. Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 36 (2007) 1-7
16. De La Porte S., Morin S., and Koenig J. Characteristics of skeletal muscle in mdx mutant mice. Int. Rev. Cytol. 191 (1999) 99-148
17. De Luca A., Nico B., Liantonio A., Didonna M.P., Fraysse B., Pierno S., Burdi R., Mangieri D., Rolland J.F., Camerino C., Zallone A., Confalonieri P., Andreetta F., Arnoldi E., Courdier-Fruh I., Magyar J.P., Frigeri A., Pisoni M., Svelto M., and Conte Camerino D. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am. J. Pathol. 166 (2005) 477-489
18. Druker B.J., and Lydon N.B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105 (2000) 3-7
19. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., and Zimmermann J. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996) 561-566
20. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
21. Farini A., Meregalli M., Belicchi M., Battistelli M., Parolini D., D'Antona G., Gavina M., Ottoboni L., Constantin G., Bottinelli R., and Torrente Y. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. J. Pathol. 213 (2007) 229-238
22. Gambacorti-Passerini C., Tornaghi L., Franceschino A., Piazza R., Córneo G., and Pogliani E. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat. Med. 13 (2007) 13-14
23. Gosselin L.E., and McCormick K.M. Targeting the immune system to improve ventilatory function in muscular dystrophy. Med. Sci. Sports Exerc. 36 (2004) 44-51
24. Granchelli J.A., Pollina C., and Hudecki M.S. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul. Disord. 10 (2000) 235-239
25. Grounds M.D., Radley H.G., Lynch G.S., Nagaraju K., and De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol. Dis. 31 (2008) 1-19
26. Gu J.J., Zhang N., He Y.W., Koleske A.J., and Pendergast A.M. Defective T cell development and function in the absence of Abelson kinases. J. Immunol. 179 (2007) 7334-7343
27. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 9 (2004) 271-281
28. Hatfield A., Owen S., and Pilot P.R. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat. Med. 13 (2007) 13
29. Kerkelä R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., Rosenzweig A., Salomon R.N., Van Etten R.A., Alroy J., Durand J.B., and Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12 (2006) 908-916
30. Larmonier N., Janikashvili N., DaCasse C.J., Larmonier C.B., Cantrell J., Situ E., Lundeen T., Bonnotte B., and Katsanis E. J. Immunol. 181 (2008) 6955-6963
31. Lasky J.A., and Brody A.R. Interstitial fibrosis and growth factors. Environ. Health Perspect. 108 (2000) 751-762
32. Leipner C., Grün K., Müller A., Buchdunger E., Borsi L., Kosmehl H., Berndt A., Janik T., Uecker A., Kiehntopf M., and Böhmer F.D. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis. Cardiovasc. Res. 79 (2008) 118-126
33. Morrison J., Palmer D.B., Cobbold S., Partridge T., and Bou-Gharios G. Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse. Am. J. Pathol. 166 (2005) 1701-1710
34. Moxley III R.T., Ashwal S., Pandya S., Connolly A., Florence J., Mathews K., Baumbach L., McDonald C., Sussman M., and Wade C. Practice parameter: corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64 (2005) 13-20
35. Nakatani M., Takehara Y., Sugino H., Matsumoto M., Hashimoto O., Hasegawa Y., Murakami T., Uezumi A., Takeda S., Noji S., Sunada Y., and Tsuchida K. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J. 22 2 (2008) 477-487
36. Oft M., Peli J., Rudaz C., Schwarz H., Beug H., and Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10 (1996) 2462-2477
37. Plattner R., Kadlec L., DeMali K.A., Kazlauskas A., and Pendergast A.M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13 (1999) 2400-2411
38. Radley H.G., De Luca A., Lynch G.S., and Grounds M.D. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int. J. Biochem. Cell Biol. 39 (2007) 469-477
39. Rokosz L.L., Beasley J.R., Carroll C.D., Lin T., Zhao J., Appell K.C., and Webb M.L. Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin. Ther. Targets 12 (2008) 883-903
40. Salgia R., Quackenbush E., Lin J., Souchkova N., Sattler M., Ewaniuk D.S., Klucher K.M., Daley G.Q., Kraeft S.K., Sackstein R., Alyea E.P., von Andrian U.H., Chen L.B., Gutierrez-Ramos J.C., Pendergast A.M., and Griffin J.D. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 94 (1999) 4233-4246
41. Seggewiss R., Price D.A., and Purbhoo M.A. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy 10 (2008) 633-641
42. Sime P.J., and O'Reilly K.M. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin. Immunol. 99 (2001) 308-319
43. Tsuchida K., Sunada Y., Noji S., Murakami T., Uezumi A., and Nakatani M. Inhibitors of the TGF-beta superfamily and their clinical applications. Mini Rev. Med. Chem. 6 (2006) 1255-1261
44. Van Etten R.A. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell. Biol. 9 (1999) 179-186
45. Vittal R., Zhang H., Han M.K., Moore B.B., Horowitz J.C., and Thannickal V.J. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J. Pharmacol. Exp. Ther. 321 (2007) 35-44
46. Vuorinen K., Gao F., Oury T.D., Kinnula V.L., and Myllärniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp. Lung Res. 33 (2007) 357-373
47. Wang S., Wilkes M.C., Leof E.B., and Hirschberg R. Imatinib mesylate blocks a non-Smad TGF - pathway and reduces renal fibrogenesis in vivo. FASEB J. 19 (2005) 1-11
48. Wolf A.M., Wolf D., Rumpold H., Ludwiczek S., Enrich B., Gastl G., Weiss G., and Tilg H. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 13622-13627
49. Wong C.K., and Lam C.W.K. Clinical applications of cytokine assays. Adv. Clin. Chem. 37 (2003) 1-46
50. Yoshiji H., Noguchi R., Kuriyama S., Ikenaka Y., Yoshii J., Yanase K., Namisaki T., Kitade M., Masaki T., and Fukui H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G907-913